Study of a new medicine for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 85 years old.
- You were diagnosed with Parkinson's within the last 5 years.
- You have not started Parkinson's medication yet, or you have been on a stable dose for at least 3 months.
- Your Parkinson's symptoms are mild to moderate (Hoehn and Yahr stage 1 to 2.5).
- You are willing to have a spinal tap (lumbar puncture) to check a protein marker.
- You are not taking certain medications that could interact with the study drug.
- You do not have other serious neurological conditions or certain genetic mutations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.